title: Efficacy and safety of the combination imidacloprid 10 % / moxidectin 1.0 % spot-on (Advocate(®) spot-on for small cats and ferrets) in the treatment of ear mite infection (Otodectes cynotis) in ferrets.
abstract: In this study, the efficacy and safety of a treatment with the combination imidacloprid 10 %/ moxidectin 1.0 % spot-on (Advocate(®) spot-on for small cats and ferrets) was tested in 39 ferrets naturally infested with ear mites (Otodectes cynotis). The study was performed as a multicentre, non-randomised, non-controlled (all study animals were treated) and non-blinded clinical field study in two French veterinary practices. Four visits (day (D) 0 = inclusion and first treatment, D14 = second treatment, D28 = possible third treatment, D56 = termination) were planned. The dosage was one pipet per ferret (designed for cats weighing up to 4 kg, corresponding to a dose of moxidectin ranging from 2.2 to 5 mg/kg body weight) two or three times at 14-days intervals (at D0, D14 and possibly D28 depending on the parasitological examination of the ears at D28). The main efficacy criterion was the absence of the parasite (all stages incl. eggs, larvae, nymphs and adults) from ear scrapings by microscopic examination. At D28 after two treatments (D0 and D14), 76.9 % (30/39) of animals were cured. Only 23 % (9/39) needed a third treatment. At day 56, 100 % were cured. Local symptoms (inflammation and pruritus) were consistently improved (50.6 % improvement at D14, 81.0 % at D28 and 97.9 % at D56) as well as the abnormal cerumen production (14.7 % improvement at D14, 77.7 % at D28 and 100.0 % at D56). No general symptoms were noticed during the study (general health and skin aspect). Advocate(®) spot-on for small cats and ferrets is an effective and safe treatment for ear mite infection in ferrets. Two or three treatments administered in 14-days intervals to ferrets infested with ear mites provided 100 % parasitological cure on D56.
authors: Bayer Santé Division Santé Animale, Puteaux, France. christophe.lesueur@bayer.com
authors: Christophe
authors: C
authors: Le Sueur
authors: Sophie
authors: S
authors: Bour
authors: Roland
authors: R
authors: Schaper
mesh_terms: D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D004423:Ear / Q000469:parasitology; D004427:Ear Diseases / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D005260:Female; D005289:Ferrets / Q000469:parasitology*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary
chemical_list: D000977:Antiparasitic Agents; D004338:Drug Combinations; D007093:Imidazoles; D018942:Macrolides; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; C027837:moxidectin